Better Artificial Intelligence Stock: Aehr Test Systems vs. KLA Corporation

KLA is presented as the stronger semiconductor-equipment investment, reporting FY2026 revenue of $13.6 billion (+11.7% YoY), net income of $4.8 billion, 35.6% net margin and $3.8 billion in free cash flow. Aehr Test Systems reported FY2026 revenue of $50.0 million (-15.2% YoY), a $7.1 million net loss and negative $5.4 million free cash flow, despite Q4 sales rising to $18.8 million and record bookings of $60.7 million. KLA trades at 33.1x forward P/E versus Aehr's 127.2x, supporting the article's preference for KLA's profitability, competitive moat and more reasonable valuation.

Analysis

The investable distinction is not simply quality versus growth: KLAC monetizes rising process complexity regardless of which end-market wins, while AEHR requires several discrete capacity ramps to occur on schedule. Advanced-node yield learning and HBM packaging intensity should raise inspection content per wafer, supporting KLAC’s service mix, utilization-linked spares demand, and pricing power through the next 12-18 months. AMAT is the closest liquid substitute, but KLAC’s process-control exposure is the cleaner expression of higher defect sensitivity at leading-edge nodes.

AEHR’s booking momentum is only valuable if it converts into diversified shipments and positive operating cash flow; its order profile can be lumpy enough that a delayed customer qualification creates an outsized revenue and multiple reset. The key second-order risk is that slower EV SiC adoption does not merely defer equipment demand: it can leave customers with adequate installed burn-in capacity, extending the digestion period by several quarters. Conversely, a genuine HBM qualification win would broaden AEHR’s addressable market and could force a sharp rerating, but that outcome needs independent evidence of repeat orders rather than a single-quarter bookings signal.

Near term, KLAC is vulnerable to a broad semiconductor-equipment de-rating or tighter China restrictions, yet its recurring revenue stream and FCF cushion make it relatively defensible versus capital-equipment peers. Over 1-3 months, TSM capex commentary, HBM supplier capacity plans, and any export-control implementation detail are the relevant catalysts; over 6-18 months, the decisive variable is whether leading-edge wafer complexity offsets China revenue friction. Consensus may be too complacent on KLAC’s China/export sensitivity, but too willing to capitalize AEHR’s prospective AI exposure before its economics prove scalable.

Key Decisions for Investors

• Initiate/maintain a 6-12 month long KLAC versus short AEHR pair, sized beta-neutral: KLAC offers exposure to leading-edge process complexity while AEHR carries execution, concentration, and cash-conversion risk. Target 15-25% relative return; exit if AEHR reports two consecutive quarters of diversified revenue growth with positive operating cash flow, or if KLAC materially cuts FY guidance.
• For long-only semiconductor exposure, prefer KLAC over AMAT on a 6-18 month horizon where the mandate seeks AI/HBM leverage with lower cyclicality; reassess if TSM’s leading-edge capex outlook is cut or China restrictions reduce KLAC’s revenue outlook by more than management’s current mitigation assumptions.
• Do not chase AEHR on bookings alone. Place an event-driven watch alert for disclosed HBM customer qualification, repeat production orders, and a path to positive FCF; only consider a tactical long after verification, using a tight risk limit below the post-catalyst support level because valuation leaves little room for shipment delays.
• Hedge KLAC’s 1-3 month policy risk with a small SMH put spread around key U.S. export-control announcements or major foundry capex updates, rather than reducing the core position; a broad equipment multiple compression is the more immediate downside than company-specific competitive erosion.